Pharma Mar Stock Falls 22% After Zepzelca Cancer Drug Trial Fails Primary Endpoint

Spanish pharmaceutical company Pharma Mar's stock dropped 22% on June 12 after its experimental lung cancer drug Zepzelca failed to meet the primary endpoint of overall survival in a Phase 3 clinical trial. The drug, developed in partnership with Jazz Pharmaceuticals, did not demonstrate superiority over researcher-selected controls in either monotherapy or combination with irinotecan. Jazz Pharmaceuticals' stock fell 2.0%. The results have been submitted to the FDA for discussion of post-marketing requirements.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments